Taken together, our data show that PYC administration effectively inhibited ASD-induced pulmonary inflammation and suppressed MMP-9 expression, highlighting PYC as a potential therapeutic agent for treating ASD-driven pulmonary inflammation. Here, MMP9 is linked to inflammatory response.